ExplainedHealth
A cancer vaccine made for one patient: how the mRNA melanoma shot works, and what the trial did and did not show
Full results presented in Madrid on Saturday show Moderna and Merck's personalised vaccine cut the risk of melanoma returning by 42%. What a 'cancer vaccine' actually does, how each dose is built, and why doctors are still waiting on the most important number.
The short answer
Intismeran autogene is not a vaccine that prevents cancer. It is a treatment given after surgery: doctors sequence the patient's removed tumour, pick up to 34 mutations found only in that cancer, and make an mRNA shot that teaches the immune system to recognise and destroy any cancer cells left behind. Given with the immunotherapy drug Keytruda in the INTerpath-001 trial of 1,137 people with high-risk melanoma, it cut the risk of relapse or death by 42% compared with Keytruda alone. Whether it helps patients live longer is not yet known, and cost and manufacturing speed remain open questions.
Is this a vaccine against cancer?
Not in the usual sense. It does not stop healthy people getting cancer.
Most vaccines are given to prevent disease. Intismeran autogene is a treatment, a “therapeutic” vaccine, given to people who already have cancer and have had it removed by surgery. Its job is to stop the disease coming back.
Melanoma, a skin cancer that can spread quickly to other organs, often returns after an operation because a few cancer cells survive unseen. The vaccine is meant to train the body’s immune system to find and kill those cells.
How is each dose made?
From the patient’s own tumour, which is why no two doses are alike.
Cancer cells carry mutations that healthy cells do not. Some of these produce faulty proteins, called neoantigens, that the immune system can learn to treat as foreign. After surgery, the removed tumour is sequenced, and software, reported to be AI-assisted, chooses up to 34 of the targets most likely to provoke a strong immune response.
An mRNA molecule carrying the instructions for those targets is then manufactured for that one person. Once injected, the body’s cells read the instructions and display the targets, and the immune system learns to recognise them. It is the same basic technology Moderna used for its Covid-19 vaccine, pointed at a cancer instead of a virus.
In the trial, the vaccine was given alongside pembrolizumab, sold as Keytruda, an immunotherapy drug that takes the brakes off the immune system. The idea is that one shows the immune cells what to attack, and the other lets them attack harder.
What did the trial find?
Fewer patients relapsed. INTerpath-001 enrolled 1,137 people with high-risk melanoma, stage IIB to IV, after surgery. Two-thirds got the vaccine plus Keytruda; the rest got Keytruda and a placebo.
After a median follow-up of just over two years, 82.2% of those on the combination were alive and free of the cancer, against 70.0% on Keytruda alone. That works out to a 42% lower risk of relapse or death, and a 38% lower risk of the cancer spreading to distant organs. The benefit took time to show: for the first six months the two groups did about the same, and after that the risk in the vaccine group was 58% lower.
Professor Georgina Long of Melanoma Institute Australia, who led the trial, said it “sets a new benchmark for adjuvant therapy in melanoma”.
Keytruda alone against Keytruda with the personalised vaccine
What did it not show?
That patients live longer. Overall survival, the measure doctors and regulators care most about, is still immature. The figures so far lean towards the vaccine but are not statistically significant, and follow-up continues.
Side effects were more common with the vaccine, mostly fever, injection-site pain and flu-like illness, described by investigators as mild and short-lived. Serious treatment-related side effects were similar in both groups, and no death was attributed to the vaccine.
Why does making it matter so much?
Because a personalised drug has to be built, quickly, for every patient. In the trial, manufacturing worked for more than 99% of those in the vaccine group, but the median wait for the first dose was 64 days, and patients received a median of nine doses. Each course needs tumour sequencing, computer design and a dedicated production run.
That raises the questions health systems will ask before regulators do: how much it will cost, and whether it can be made fast enough at scale. Merck and Moderna say they are talking to regulators. For patients in India and elsewhere, approval and access are still some way off; what the trial offers now is the strongest evidence yet that a cancer vaccine built for one person can work.